Single Dose Escalation Study of ONO-9054 in Healthy Volunteers
Completed · Phase 1 · Has a placebo group
Conditions studied: Healthy Adult Subjects
In brief
The primary objective of this study is to evaluate the safety and tolerability of ascending single doses of ONO-9054 administered as a single drop in healthy adult subjects. The secondary objectives are to characterize the pharmacokinetic (PK) profile of ONO-9054 and its metabolite in plasma and to evaluate the pharmacodynamic (PD) profile.
Key facts
- Study ID
- NCT01508988
- Run by
- Ono Pharma USA Inc
- People needed
- 48
- Starts
- 2012-01-01
- Last updated by the study team
- 2012-06-14
Who can join
Age: 18 and older, up to 64. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Healthy male or female subjects, aged 18-64 inclusive
- Body mass index (BMI) of 19-35 kg/m2 (inclusive)
- IOP measurement oculus uterque (OU, both eyes) < 21 mm Hg (inclusive) at screening and Day -1
- Best corrected visual acuity (BCVA) 20/30 or better (Snellen Equivalent) at both the screening visit and Day -1
You may not qualify if…
- Any history of severe ocular trauma in either eye at any time
- Any history of previous intraocular or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of the screening visit in either eye
- Current or chronic history of ocular infection within the past 3 months of screening visit in either eye OR ongoing or recurrent ocular inflammation in either eye
- At the ophthalmic investigator's discretion, any subjects who have a history of any significant ocular conditions in either eye that would contraindicate the use of the study medication, or that might affect the study conduct, or the interpretation of the study results
- Use of any non-diagnostic topical ophthalmic solutions except for sponsor-recommended tear substitutes from admission to the study unit through the duration of the study
- History of clinically significant drug or food allergy, positive HIV, hepatitis B or C at screening
Where it is running
- Covance Phase 1 Unit — Dallas, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.